A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Advanced cancer of the lymph nodes of follicular type at study inclusion

• The patient has relapsed or has refractory disease, after previous treatment with rituximab

• Treating physician has decided to treat the patient with a 90Y-Zevalin regimen

• The patient is >= 18 years of age

• Patient has given informed consent

Exclusion Criteria:

• Patient is unwilling or unable to give informed consent

• Patient is participating in another clinical trial